Targeted therapy in lymphomaReport as inadecuate




Targeted therapy in lymphoma - Download this document for free, or read online. Document in PDF available to download.

Journal of Hematology and Oncology

, 3:45

First Online: 23 November 2010Received: 04 November 2010Accepted: 23 November 2010

Abstract

Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal transduction pathways, which have led to the discovery and development of targeted therapeutics. The ubiquitin-proteasome and the Akt-mammalian target of rapamycin mTOR pathways are examples of pathological mechanisms that are being targeted in drug development efforts. Bortezomib a small molecule protease inhibitor and the mTOR inhibitors temsirolimus, everolimus, and ridaforolimus are some of the targeted therapies currently being studied in the treatment of aggressive, relapsed-refractory lymphoma. This review will discuss the rationale for and summarize the reported findings of initial and ongoing investigations of mTOR inhibitors and other small molecule targeted therapies in the treatment of lymphoma.

AbbreviationsDLBCLdiffuse large B-cell lymphoma

GVHDgraft-versus-host disease

HDACIshistone deacetylase inhibitors

HLHodgkin lymphoma

MCLmantle cell lymphoma

mTORmammalian target of rapamycin

NF-κBnuclear factor-κB

NHLnon-Hodgkin lymphoma

PDGFplatelet-derived growth factor

PI3Kphosphoinositide 3-kinase

WMWaldenström macroglobulinemia

Electronic supplementary materialThe online version of this article doi:10.1186-1756-8722-3-45 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Patrick B Johnston - RuiRong Yuan - Franco Cavalli - Thomas E Witzig

Source: https://link.springer.com/







Related documents